{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:47:44Z","timestamp":1792806464725,"version":"4.5.0"},"reference-count":94,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bill &amp; Melinda Gates Foundation (BMGF)","id":[{"id":"https:\/\/ror.org\/0456r8d26","id-type":"ROR","asserted-by":"crossref"}]},{"name":"CDC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>As the world is approaching the eradication of wild poliovirus serotype 1, the last of the three wild types, the question of how to maintain a polio-free world becomes imminent. To mitigate the risk of sporadic vaccine-associated paralytic polio (VAPP) caused by oral polio vaccines (OPVs) that are routinely used in global immunization programs, the Polio Antivirals Initiative (PAI) was established in 2006. The primary goal of the PAI is to facilitate the discovery and development of antiviral drugs to stop the excretion of immunodeficiency-associated vaccine-derived poliovirus (iVDPV) in B cell-deficient individuals. This review summarizes the major progress that has been made in the development of safe and effective poliovirus antivirals and highlights the candidates that have shown promising results in vitro, in vivo, and in clinical trials.<\/jats:p>","DOI":"10.3390\/pathogens13110969","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T06:27:39Z","timestamp":1730874459000},"page":"969","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Antiviral Development for the Polio Endgame: Current Progress and Future Directions"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8318-5554","authenticated-orcid":false,"given":"Hang","family":"Xie","sequence":"first","affiliation":[{"name":"Poliovirus & Picornavirus Branch, Division of Viral Diseases, National Center for Immunization and Other Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric E.","family":"Rhoden","sequence":"additional","affiliation":[{"name":"Poliovirus & Picornavirus Branch, Division of Viral Diseases, National Center for Immunization and Other Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Mei","family":"Liu","sequence":"additional","affiliation":[{"name":"Poliovirus & Picornavirus Branch, Division of Viral Diseases, National Center for Immunization and Other Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folake","family":"Ogunsemowo","sequence":"additional","affiliation":[{"name":"Poliovirus & Picornavirus Branch, Division of Viral Diseases, National Center for Immunization and Other Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo A.","family":"Mainou","sequence":"additional","affiliation":[{"name":"Poliovirus & Picornavirus Branch, Division of Viral Diseases, National Center for Immunization and Other Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Burke","sequence":"additional","affiliation":[{"name":"Bill & Melinda Gates Foundation, Seattle, WA 98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara C.","family":"Burns","sequence":"additional","affiliation":[{"name":"Poliovirus & Picornavirus Branch, Division of Viral Diseases, National Center for Immunization and Other Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0092-8674(89)90690-9","article-title":"Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily","volume":"56","author":"Mendelsohn","year":"1989","journal-title":"Cell"},{"key":"ref_2","unstructured":"WHO (2024, August 10). Poliomyelitis: Key Facts. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/poliomyelitis."},{"key":"ref_3","unstructured":"ECDC (2024, August 10). Disease Factsheet about Poliomyelitis. Available online: https:\/\/www.ecdc.europa.eu\/en\/poliomyelitis\/facts#:~:text=All%20unimmunised%20persons%20are%20susceptible%20to%20the%20infection.,with%20sero-conversion%20rates%20of%2090%E2%80%93100%25%20among%20household%20contacts."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.15585\/mmwr.mm7313a1","article-title":"Surveillance To Track Progress Toward Polio Eradication-Worldwide, 2022\u20132023","volume":"73","author":"Kishore","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.11150\/kansenshogakuzasshi1970.75.1030","article-title":"The relationship between poliovirus multiplication, the sIgA antibody response and the serum neutralizing antibody titers after trivalent oral polio vaccination","volume":"75","author":"Morimoto","year":"2001","journal-title":"Kansenshogaku Zasshi"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/infdis\/jit671","article-title":"Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination","volume":"209","author":"Wright","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41385-021-00428-0","article-title":"Mucosal immunity to poliovirus","volume":"15","author":"Connor","year":"2022","journal-title":"Mucosal Immunol."},{"key":"ref_8","unstructured":"(2024, August 10). Polio Global Eradication Initiative Fact Sheet: Vaccine-Derived Poliovirus. Available online: https:\/\/www.who.int\/docs\/default-source\/documents\/gpei-cvdpv-factsheet-march-2017.pdf?sfvrsn=1ceef4af_2."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/archpedi.1994.02170050037007","article-title":"Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease","volume":"148","author":"Prevots","year":"1994","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"ref_10","first-page":"640","article-title":"Update on Vaccine-Derived Polioviruses\u2014Worldwide, January 2014\u2013March 2015","volume":"64","author":"Diop","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1093\/infdis\/jiu184","article-title":"Vaccine-associated paralytic poliomyelitis: A review of the epidemiology and estimation of the global burden","volume":"210","author":"Platt","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1126\/science.1068284","article-title":"Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus","volume":"296","author":"Kew","year":"2002","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2017.03.013","article-title":"The Evolutionary Pathway to Virulence of an RNA Virus","volume":"169","author":"Stern","year":"2017","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mohanty, M.C., Madkaikar, M.R., Desai, M., Aluri, J., Varose, S.Y., Taur, P., Sharma, D.K., Nalavade, U.P., Rane, S.V., and Gupta, M. (2019). Natural Clearance of Prolonged VDPV Infection in a Child With Primary Immunodeficiency Disorder. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01567"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"913","DOI":"10.15585\/mmwr.mm6928a4","article-title":"Update on Immunodeficiency-Associated Vaccine-Derived Polioviruses\u2014Worldwide, July 2018\u2013December 2019","volume":"69","author":"Macklin","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.15585\/mmwr.mm7136a2","article-title":"Detection of a Highly Divergent Type 3 Vaccine-Derived Poliovirus in a Child with a Severe Primary Immunodeficiency Disorder\u2014Chongqing, China, 2022","volume":"71","author":"Yao","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/s41467-023-39094-0","article-title":"Asymptomatic immunodeficiency-associated vaccine-derived poliovirus infections in two UK children","volume":"14","author":"Singanayagam","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Cifuente, J.O., and Moratorio, G. (2019). Evolutionary and Structural Overview of Human Picornavirus Capsid Antibody Evasion. Front. Cell. Infect. Microbiol., 9.","DOI":"10.3389\/fcimb.2019.00283"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1099\/0022-1317-67-7-1283","article-title":"Antigenic structure of polioviruses of serotypes 1, 2 and 3","volume":"67","author":"Minor","year":"1986","journal-title":"J. Gen. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0969-2126(97)00261-X","article-title":"Structure of the RNA-dependent RNA polymerase of poliovirus","volume":"5","author":"Hansen","year":"1997","journal-title":"Structure"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0960-9822(00)00176-7","article-title":"Structures of poliovirus complexes with anti-viral drugs: Implications for viral stability and drug design","volume":"4","author":"Grant","year":"1994","journal-title":"Curr. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1128\/jvi.67.3.1246-1254.1993","article-title":"WIN 51711-dependent mutants of poliovirus type 3: Evidence that virions decay after release from cells unless drug is present","volume":"67","author":"Mosser","year":"1993","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/j.1460-2075.1989.tb03541.x","article-title":"Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus","volume":"8","author":"Filman","year":"1989","journal-title":"EMBO J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1128\/jvi.64.5.1934-1945.1990","article-title":"Cell-induced conformational change in poliovirus: Externalization of the amino terminus of VP1 is responsible for liposome binding","volume":"64","author":"Fricks","year":"1990","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8757","DOI":"10.1128\/JVI.74.18.8757-8761.2000","article-title":"Is the 135S poliovirus particle an intermediate during cell entry?","volume":"74","author":"Huang","year":"2000","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7745","DOI":"10.1128\/JVI.79.12.7745-7755.2005","article-title":"The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes","volume":"79","author":"Bubeck","year":"2005","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1073\/pnas.97.1.79","article-title":"Interaction of the poliovirus receptor with poliovirus","volume":"97","author":"He","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/291547a0","article-title":"Primary structure, gene organization and polypeptide expression of poliovirus RNA","volume":"291","author":"Kitamura","year":"1981","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2217\/fmb.10.40","article-title":"Expanding knowledge of P3 proteins in the poliovirus lifecycle","volume":"5","author":"Cameron","year":"2010","journal-title":"Future Microbiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.virol.2015.07.018","article-title":"Viral precursor protein P3 and its processed products perform discrete and essential functions in the poliovirus RNA replication complex","volume":"485","author":"Spear","year":"2015","journal-title":"Virology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/j.1460-2075.1989.tb08406.x","article-title":"Role of myristoylation of poliovirus capsid protein VP4 as determined by site-directed mutagenesis of its N-terminal sequence","volume":"8","author":"Marc","year":"1989","journal-title":"EMBO J."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Wang, S.H., Wang, K., Zhao, K., Hua, S.C., and Du, J. (2020). The Structure, Function, and Mechanisms of Action of Enterovirus Non-structural Protein 2C. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.615965"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1128\/JVI.72.8.6732-6741.1998","article-title":"Complete protein linkage map of poliovirus P3 proteins: Interaction of polymerase 3Dpol with VPg and with genetic variants of 3AB","volume":"72","author":"Xiang","year":"1998","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1128\/JVI.02398-10","article-title":"Analysis of poliovirus protein 3A interactions with viral and cellular proteins in infected cells","volume":"85","author":"Teterina","year":"2011","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"22012","DOI":"10.1074\/jbc.M109.031807","article-title":"Poliovirus 2C protein forms homo-oligomeric structures required for ATPase activity","volume":"284","author":"Adams","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0042-6822(79)90342-8","article-title":"Inhibition of uncoating of poliovirus by arildone, a new antiviral drug","volume":"97","author":"McSharry","year":"1979","journal-title":"Virology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0042-6822(80)90158-0","article-title":"Effect of arildone on modifications of poliovirus in vitro","volume":"105","author":"Caliguiri","year":"1980","journal-title":"Virology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0166-3542(95)00979-5","article-title":"Antipicornavirus activity of SCH 47802 and analogs: In vitro and in vivo studies","volume":"32","author":"Cox","year":"1996","journal-title":"Antivir. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1128\/AAC.41.6.1220","article-title":"SCH 48973: A potent, broad-spectrum, antienterovirus compound","volume":"41","author":"Buontempo","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1006\/jmbi.1999.3483","article-title":"Stabilization of poliovirus by capsid-binding antiviral drugs is due to entropic effects","volume":"296","author":"Tsang","year":"2000","journal-title":"J. Mol. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1592\/phco.23.3.339.32099","article-title":"Pleconaril, a novel antipicornaviral agent","volume":"23","author":"Florea","year":"2003","journal-title":"Pharmacotherapy"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1128\/AAC.29.1.30","article-title":"Oral efficacy of WIN 51711 in mice infected with human poliovirus","volume":"29","author":"McKinlay","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1203\/00006450-199904020-01026","article-title":"Pleconaril Treatment of Vaccine-Acquired Poliovirus","volume":"45","author":"Romero","year":"1999","journal-title":"Pediatr. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1099\/vir.0.18974-0","article-title":"Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis","volume":"84","author":"Buttinelli","year":"2003","journal-title":"J. Gen. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S0140-6736(04)16150-3","article-title":"Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man","volume":"363","author":"MacLennan","year":"2004","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1086\/375069","article-title":"Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: Results of 2 double-blind, randomized, placebo-controlled trials","volume":"36","author":"Hayden","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jpids\/piv015","article-title":"A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates with Enterovirus Sepsis","volume":"5","author":"Abzug","year":"2016","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1086\/318452","article-title":"Treatment of potentially life-threatening enterovirus infections with pleconaril","volume":"32","author":"Rotbart","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1473-3099(02)00277-3","article-title":"FDA panel rejects common cold treatment","volume":"2","author":"Senior","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1128\/AAC.36.1.100","article-title":"In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity","volume":"36","author":"Andries","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3201\/eid1404.070439","article-title":"Potential use of antiviral agents in polio eradication","volume":"14","author":"Purstinger","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1128\/AAC.48.5.1766-1772.2004","article-title":"In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: Novel capsid-binding inhibitors with potent antipicornavirus activity","volume":"48","author":"Barnard","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ejmech.2019.06.008","article-title":"Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses","volume":"178","author":"Egorova","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1128\/AAC.00671-09","article-title":"In vitro antiviral activity of V-073 against polioviruses","volume":"53","author":"Oberste","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e03830","DOI":"10.7554\/eLife.03830","article-title":"Dominant drug targets suppress the emergence of antiviral resistance","volume":"3","author":"Tanner","year":"2014","journal-title":"Elife"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/INF.0000000000002584","article-title":"Clearance of Immunodeficiency-associated Vaccine-derived Poliovirus Infection With Pocapavir","volume":"39","author":"Copelyn","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_57","first-page":"335","article-title":"Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model","volume":"215","author":"Collett","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1128\/AAC.00539-12","article-title":"Characterization of poliovirus variants selected for resistance to the antiviral compound V-073","volume":"56","author":"Liu","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.antiviral.2013.03.003","article-title":"Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds","volume":"98","author":"Rhoden","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2014.07.003","article-title":"H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1","volume":"110","author":"Tijsma","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"11000","DOI":"10.1073\/pnas.96.20.11000","article-title":"Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes","volume":"96","author":"Matthews","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1128\/AAC.43.10.2444","article-title":"In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease","volume":"43","author":"Patick","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/AAC.49.6.2267-2275.2005","article-title":"In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease","volume":"49","author":"Patick","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcp.2011.08.016","article-title":"Combating enterovirus replication: State-of-the-art on antiviral research","volume":"83","author":"Thibaut","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1021\/jm010469k","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics","volume":"45","author":"Dragovich","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1021\/jm030166l","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics","volume":"46","author":"Dragovich","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e0102921","DOI":"10.1128\/AAC.01029-21","article-title":"A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers","volume":"65","author":"Kankam","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"8482","DOI":"10.1128\/jvi.71.11.8482-8489.1997","article-title":"Synchronous replication of poliovirus RNA: Initiation of negative-strand RNA synthesis requires the guanidine-inhibited activity of protein 2C","volume":"71","author":"Barton","year":"1997","journal-title":"J. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1128\/jvi.64.3.1156-1163.1990","article-title":"Structural organization of poliovirus RNA replication is mediated by viral proteins of the P2 genomic region","volume":"64","author":"Bienz","year":"1990","journal-title":"J. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1074\/jbc.274.11.6992","article-title":"Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication","volume":"274","author":"Pfister","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1128\/JVI.74.9.4146-4154.2000","article-title":"Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives","volume":"74","author":"Shimizu","year":"2000","journal-title":"J. Virol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"9054","DOI":"10.1128\/jvi.71.12.9054-9064.1997","article-title":"Inhibition of endoplasmic reticulum-to-Golgi traffic by poliovirus protein 3A: Genetic and ultrastructural analysis","volume":"71","author":"Doedens","year":"1997","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"8158","DOI":"10.1128\/JVI.75.17.8158-8165.2001","article-title":"Poliovirus 3A protein limits interleukin-6 (IL-6), IL-8, and beta interferon secretion during viral infection","volume":"75","author":"Dodd","year":"2001","journal-title":"J. Virol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cell.2010.03.050","article-title":"Viral reorganization of the secretory pathway generates distinct organelles for RNA replication","volume":"141","author":"Hsu","year":"2010","journal-title":"Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/acsinfecdis.5b00122","article-title":"Mechanism of Poliovirus Resistance to Host Phosphatidylinositol-4 Kinase III beta Inhibitor","volume":"2","author":"Arita","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1021\/acsinfecdis.9b00038","article-title":"Poliovirus Evolution toward Independence from the Phosphatidylinositol-4 Kinase III beta\/Oxysterol-Binding Protein Family I Pathway","volume":"5","author":"Arita","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1128\/jvi.69.7.4189-4197.1995","article-title":"The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus","volume":"69","author":"Heinz","year":"1995","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1128\/AAC.00934-08","article-title":"Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307","volume":"53","author":"Thibaut","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1128\/JVI.02249-10","article-title":"Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity","volume":"85","author":"Arita","year":"2011","journal-title":"J. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.antiviral.2011.03.187","article-title":"Towards the design of combination therapy for the treatment of enterovirus infections","volume":"90","author":"Thibaut","year":"2011","journal-title":"Antivir. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1128\/AAC.23.5.671","article-title":"Therapeutic activity of enviroxime against rhinovirus infection in volunteers","volume":"23","author":"Phillpotts","year":"1983","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1128\/jvi.41.1.313-318.1982","article-title":"Inhibition of poliovirus polymerase by guanidine in vitro","volume":"41","author":"Tershak","year":"1982","journal-title":"J. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1128\/jvi.66.4.1971-1976.1992","article-title":"Gliotoxin: Inhibitor of poliovirus RNA synthesis that blocks the viral RNA polymerase 3Dpol","volume":"66","author":"Rodriguez","year":"1992","journal-title":"J. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev. Med. Virol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/82191","article-title":"The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen","volume":"6","author":"Crotty","year":"2000","journal-title":"Nat. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1073\/pnas.111085598","article-title":"RNA virus error catastrophe: Direct molecular test by using ribavirin","volume":"98","author":"Crotty","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"8410","DOI":"10.1128\/JVI.00078-16","article-title":"Poliovirus Polymerase Leu420 Facilitates RNA Recombination and Ribavirin Resistance","volume":"90","author":"Kempf","year":"2016","journal-title":"J. Virol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1021\/acs.jmedchem.8b01482","article-title":"In Vitro Antiviral Activity of New Oxazoline Derivatives as Potent Poliovirus Inhibitors","volume":"62","author":"Madia","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Abdelnabi, R., Geraets, J.A., Ma, Y., Mirabelli, C., Flatt, J.W., Domanska, A., Delang, L., Jochmans, D., Kumar, T.A., and Jayaprakash, V. (2019). A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses. PLoS Biol., 17.","DOI":"10.1371\/journal.pbio.3000281"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.celrep.2014.12.054","article-title":"Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein","volume":"10","author":"Strating","year":"2015","journal-title":"Cell Rep."},{"key":"ref_91","unstructured":"(2024, August 10). Antiretroviral Drug Discovery and Development, Available online: https:\/\/www.niaid.nih.gov\/diseases-conditions\/antiretroviral-drug-development."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Mosier, P.D., Chiang, M.J., Lin, Z., Gao, Y., Althufairi, B., Zhou, Q., Musayev, F., Safo, M.K., Xie, H., and Desai, U.R. (2016). Broad Spectrum Anti-Influenza Agents by Inhibiting Self-Association of Matrix Protein 1. Sci. Rep., 6.","DOI":"10.1038\/srep32340"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"De Rosa, M.C., Purohit, R., and Garcia-Sosa, A.T. (2023). Drug repurposing: A nexus of innovation, science, and potential. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-44264-7"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/11\/969\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:27:01Z","timestamp":1760113621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/11\/969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":94,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["pathogens13110969"],"URL":"https:\/\/doi.org\/10.3390\/pathogens13110969","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]}}}